Advertisement

Psychopharmacology

, Volume 235, Issue 8, pp 2245–2256 | Cite as

Interactions between kappa and mu opioid receptor agonists: effects of the ratio of drugs in mixtures

  • Vanessa Minervini
  • Hannah Y. Lu
  • Jahnavi Padarti
  • Daniela C. Osteicoechea
  • Charles P. France
Original Investigation
  • 210 Downloads

Abstract

Rationale

Pain is the leading reason for seeking health care, and mu opioid receptor agonists continue to be prescribed despite well-documented adverse effects. Kappa opioid receptor agonists have antinociceptive effects with little to no abuse liability and might be useful for treating pain in mixtures. Kappa:mu opioid mixtures might be useful if therapeutic effects of each drug can be selectively increased while reducing or avoiding the adverse effects that occur with larger doses of each drug alone.

Objective

This study characterized the effects of the kappa opioid receptor agonist spiradoline alone (0.32–56 mg/kg) and in 1:10, 1:3, 1:1, and 3:1 mixtures with the mu opioid receptor agonists morphine (1.0–32 mg/kg) and etorphine (1–10 μg/kg) on warm water tail-withdrawal latency, body temperature, responding for food, and fecal output in male Sprague-Dawley rats (n = 24).

Results

Antinociceptive effects were greater than additive for 1:10 and 1:3 spiradoline:morphine mixtures and for 1:10, 1:3, and 1:1 spiradoline:etorphine mixtures. The potency of spiradoline to produce hypothermia was greater with 1:3 and 3:1 spiradoline:etorphine mixtures but not with 1:10 or 1:1 mixtures or with any spiradoline:morphine mixture. The effects of 1:3 spiradoline:morphine on responding for food were additive, whereas 1:1 and 3:1 were greater than additive. Spiradoline did not significantly alter morphine-induced decreases in fecal output.

Conclusions

Overall, mixtures of kappa and mu opioids might have therapeutic potential for treating pain, particularly when the mixture has a greater ratio of mu to kappa agonist. If adverse effects of each constituent drug are reduced or avoided, then kappa:mu mixtures might be advantageous to mu opioids alone.

Keywords

Opioids Drug mixtures Drug interactions Antinociception Rats 

Notes

Acknowledgements

The authors thank Lisa Gerak, David Maguire, and Gregory Collins for their helpful comments on the manuscript.

Funding information

This work was supported by the National Institutes of Health (NIH) National Institute on Drug Abuse [Grants K05DA017918, T32DA031115, F32DA043348] and the Welch Foundation [Grant AQ-0039].

Compliance with ethical standards

The experimental protocol was approved by the Institutional Animal Care and Use Committee at the University of Texas Health Science Center at San Antonio and in accordance with guidelines set forth by the Guide for the Care and Use of Laboratory Animals (2011).

Conflict of interest

The authors declare that they have no conflict of interest.

Disclaimer

The content expressed here is solely the responsibly of the authors and does not necessarily represent the views of the NIH.

Supplementary material

213_2018_4920_MOESM1_ESM.pdf (241 kb)
Online Resource 1 (PDF 241 kb)
213_2018_4920_MOESM2_ESM.pdf (269 kb)
Online Resource 2 (PDF 269 kb)

References

  1. Binder W, Carmody J, Walker J (1999) Effect of gender on anti-inflammatory and analgesic actions of two k-opioids. J Pharmacol Exp Ther 292:303–309Google Scholar
  2. Briggs SL, Rech RH, Sawyer (1998) Kappa antinociceptive activity of spiradoline in the cold-water tail-flick assay in rats. Pharmacol Biochem Behav 60:467–472CrossRefPubMedGoogle Scholar
  3. Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG, Bucher-Bartelson B, Green JL (2015) Trends in opioid analgesia abuse and mortality in the United States. N Engl J Med 372:241–248CrossRefPubMedGoogle Scholar
  4. Dosaka-Akita K, Tortella FC, Holaday JW, Long JB (1993) The kappa opioid agonist U-50,488H antagonizes respiratory effects of mu opioid receptor agonists in conscious rats. J Pharmacol Exp Ther 264:631–637PubMedGoogle Scholar
  5. Dykstra LA, Gmerek DE, Winger G, Woods JE (1987) Kappa opioids in rhesus monkeys. I. Diuresis, sedations, analgesia, and discriminative stimulus effects. J Pharmacol Exp Ther 242:413–420PubMedGoogle Scholar
  6. Elhabazi K, Ayachi S, Ilien B, Simonin F (2014) Assessment of morphine-induced hyperalgesia and analgesic tolerance in mice using thermal and mechanical nociceptive modalities. J Vis Exp 89:e5164Google Scholar
  7. Gallantine EL, Meert TF (2008) Antinociceptive and adverse effects of mu- and kappa-opioid receptor agonists: a comparison of morphine and U50488-H. Basic Clin Pharmacol Toxicol 103:419–427CrossRefPubMedGoogle Scholar
  8. Geller EB, Hawk C, Keinath SH, Tallarida RJ, Adler MW (1983) Subclass of opioids based on body temperature change in rats: acute subcutaneous administration. J Pharmacol Exp Ther 225:391–398PubMedGoogle Scholar
  9. Grabovsky Y, Tallarida RJ (2004) Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. J Pharmacol Exp Ther 310:981–986CrossRefPubMedGoogle Scholar
  10. Gunther T, Dasgupta P, Mann A, Miess E, Kliewer A, Fritzwanker S, Steinborn R, Schulz S (2017) Targeting multiple opioid receptors—improved analgesics with reduced side effects? Br J Pharmacol.  https://doi.org/10.1111/bph.13809
  11. Howell LL, Bergman J, Morse WH (1988) Effects of levorphanol and several kappa-selective opioids on respiration and behavior in rhesus monkeys. J Pharmacol Exp Ther 245:364–372PubMedGoogle Scholar
  12. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH (2010) The prevalence of chronic pain in United States adults: results of an internet-based survey. J Pain 11:1230–1239CrossRefPubMedGoogle Scholar
  13. Kivell B, Prisinzano TW (2010) Kappa opioids and the modulation of pain. Psychopharmacology 210:109–119CrossRefPubMedGoogle Scholar
  14. Ko MC, Husbands SM (2009) Effects of atypical k-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates. J Pharmacol Exp Ther 328:193–200CrossRefPubMedGoogle Scholar
  15. Levy B, Paulozzi L, Mack KA, Jones CM (2015) Trends in opioid analgesic-prescribing rates by specialty, U.S., 2017–2012. Am J Prev Med 49:409–413CrossRefPubMedPubMedCentralGoogle Scholar
  16. Maguire DR, France CP (2014) Impact of efficacy at the mu-opioid receptor on antinociceptive effects of combinations of mu-opioid receptor agonists and cannabinoid receptor agonists. J Pharmacol Exp Ther 351:283–289CrossRefGoogle Scholar
  17. Maguire DR, France CP (2016) Additive antinociceptive effects of mixtures of the k-opioid receptor agonist spiradoline and the cannabinoid receptor agonist CP55940 in rats. Behav Pharmacol 27:69–72Google Scholar
  18. McPherson J, Rivero G, Baptist M, Llorente J, Al-Sabah S, Krasel C, Dewey WL, Bailey CP, Rosethorne EM, Charlton SJ, Henderson G, Kelly E (2010) Mu-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol 78:756–766CrossRefPubMedPubMedCentralGoogle Scholar
  19. Mello NK, Negus SS (1998) Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J Pharmacol Exp Ther 286:812–824PubMedGoogle Scholar
  20. Miaskowski C, Levine JD (1992) Antinociception produced by receptor selective opioids: modulation of spinal antinociceptive effects by supraspinal opioids. Brain Res 595:32–38CrossRefPubMedGoogle Scholar
  21. Minervini V, Dahal S, France CP (2017) Behavioral characterization of kappa opioid receptor agonist spiradoline and cannabinoid receptor agonist CP55940 mixtures in rats. J Pharmacol Exp Ther 360:280–287CrossRefPubMedPubMedCentralGoogle Scholar
  22. Morgan MM, Christie MJ (2011) Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human. Br J Pharmacol 164:1322–1334CrossRefPubMedPubMedCentralGoogle Scholar
  23. Nahil RL (2015) Estimates of pain prevalence and severity in adults: United States, 2012. J Pain 16:769–780CrossRefGoogle Scholar
  24. Negus SS, Mello NK (2002) Effects of mu-opioid agonists on cocaine- and food-maintained responding and cocaine discrimination in rhesus monkeys: role of mu-agonist efficacy. J Pharmacol Exp Ther 300:1111–1121CrossRefPubMedGoogle Scholar
  25. Negus SS, Schrode KA, Stevenson GW (2008) Mu/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability. Exp Clin Psychopharmacol 16:386–399CrossRefPubMedPubMedCentralGoogle Scholar
  26. Peters GR, Ward NJ, Antal EG, Lai PY, deMaar EW (1987) Diuretic actions in man of a selective k opioid agonist: U-62,066E. J Pharmacol Exp Ther 240:128–131PubMedGoogle Scholar
  27. Pfeiffer A, Brantl V, Herz A, Emrich HM (1986) Psychotomimesis mediated by kappa opiate receptors. Science 233:774–776CrossRefPubMedGoogle Scholar
  28. Porreca F, Mosberg HI, Hurst R, Hruby VJ, Burks TF (1984) Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J Pharmacol Exp Ther 230:341–348PubMedGoogle Scholar
  29. Rech RH, Mokler DJ, Briggs SL (2012) Effects of combined opioids on pain and mood in mammals. Pain Res Treat 2012:145965 (Article ID), 11 pagesPubMedPubMedCentralGoogle Scholar
  30. Roger T, Bardon T, Ruckebusch (1994) Comparative effects of my and kappa opiate agonists on the cecocolic motility in the pony. Can J Vet Res 58:163–166PubMedPubMedCentralGoogle Scholar
  31. Rudd RA, Aleshire N, Zibbell JE, Gladden RM (2016) Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR Morb Mortal Wkly Rep 64:1378–1382CrossRefPubMedGoogle Scholar
  32. Sakakihara M, Imamachi N, Saito Y (2016) Effects of intrathecal k-opioid receptor agonist on morphine-induced itch and antinociception in mice. Reg Anesth Pain Med 41:69–74CrossRefPubMedGoogle Scholar
  33. Shippenberg TS, Stein C, Huber A, Millan MJ, Herz A (1988) Motivational effects of opioids in an animal model of prolonged inflammatory pain: alteration in the effects of kappa- but not of mu-receptor agonists. Pain 35:179–186CrossRefPubMedGoogle Scholar
  34. St. Sauver JL, Warner DO, Yawn BP, Jacobson DJ, McGree ME, Pankratz JJ, Melton LJ, Roger VL, Ebbert JO, Rocca WA (2013) Why patients visit their doctors: assessing the most prevalent conditions in a defined American population. Mayo Clin Proc 88:56–67CrossRefPubMedPubMedCentralGoogle Scholar
  35. Stevenson GW, Folk JE, Linsenmayer DV, Rice KC, Negus SS (2003) Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception. J Pharmacol Exp Ther 307:1054–1064CrossRefPubMedGoogle Scholar
  36. Sutters KA, Miaskowski C, Taiwo YO, Levine JD (1990) Analgesic synergy and improved motor function produced by combinations of mu-delta and mu-kappa opioids. Brain Res 530:290–294CrossRefPubMedGoogle Scholar
  37. Tallarida RJ (2006) An overview of drug combination analysis with isobolograms. J Pharm Exp Ther 319:1–7CrossRefGoogle Scholar
  38. Tallarida RJ (2011) Quantitative methods for assessing drug synergism. Genes Cancer 2:1003–1008CrossRefPubMedPubMedCentralGoogle Scholar
  39. Tavani A, Gamibino MC, Petrillo P (1984) The opioid K-selective compound U50488H does not inhibit intestinal propulsion in rats. J Pharm Pharmacol 36:2073–2077CrossRefGoogle Scholar
  40. Towsend EA, Naylor JE, Negus SS, Edwards SR, Qureshi HN, McLendon HW, McCurdy CR, Kapanda CN, do Carmo JM, da Silva FS, Hall JE, Sufka KJ, Freeman KB (2017) Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats. Psychopharmacology (Berl).  https://doi.org/10.1007/s00213-017-4652-3
  41. Tyers MB (1980) A classification of opiate receptors that mediate antinociception in animals. Br J Pharmacol 69:503–512CrossRefPubMedPubMedCentralGoogle Scholar
  42. Verborgh CML, Camu F, Meert TF (1997) Interactions between sufentanil and U-50488H with respect to antinociception and respiratory depression in rats. Acta Anaesthesiol Scand 41:895–902CrossRefPubMedGoogle Scholar
  43. Volkow ND, McLellan AT (2016) Opioid abuse in chronic pain—misconceptions and mitigation strategies. N Engl J Med 374:1253–1263CrossRefPubMedGoogle Scholar
  44. Walker EA, Zernig G, Young AM (1998) In vivo apparent affinity and efficacy estimates for mu opiates in a rat tail-withdrawal assay. Psychopharmacology 136:15–23CrossRefPubMedGoogle Scholar
  45. Ward SJ, Takemori AE (1982) Relative involvement of mu, kappa, and delta receptor mechanisms in opiate-mediated antinociception in mice. J Pharmacol Exp Ther 224:525–530Google Scholar
  46. Woods JH, Winger G (1987) Behavioral characterization of opioid mixed agonist-antagonists. Drug Alcohol Depend 20:303–315CrossRefPubMedGoogle Scholar
  47. Zaki PA, Keith DE Jr, Brine GA, Carroll FI, Evans CJ (2000) Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation? J Pharmacol Exp Ther 292:1127–1134PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PharmacologyUniversity of Texas Health Science CenterSan AntonioUSA
  2. 2.Addiction Research, Treatment and Training (ARTT) Center of ExcellenceUniversity of Texas Health Science CenterSan AntonioUSA
  3. 3.Department of PsychiatryUniversity of Texas Health Science CenterSan AntonioUSA

Personalised recommendations